Barclays Issues Positive Forecast for West Pharmaceutical Services (NYSE:WST) Stock Price

West Pharmaceutical Services (NYSE:WST) had its price target raised by Barclays from $440.00 to $500.00 in a research report report published on Friday,Benzinga reports. Barclays currently has an overweight rating on the medical instruments supplier’s stock.

Other analysts also recently issued reports about the stock. BNP Paribas Exane started coverage on shares of West Pharmaceutical Services in a research report on Monday, July 13th. They set an “outperform” rating and a $447.00 price objective on the stock. UBS Group raised their price target on West Pharmaceutical Services from $340.00 to $415.00 and gave the company a “buy” rating in a report on Wednesday, September 9th. Wall Street Zen downgraded West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research report on Saturday, October 24th. TD Cowen upped their price objective on West Pharmaceutical Services from $410.00 to $420.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Finally, Zacks Research cut West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 12th. Twelve analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $409.67.

West Pharmaceutical Services Stock Performance

NYSE:WST opened at $412.73 on Friday. The stock has a 50-day simple moving average of $367.76 and a two-hundred day simple moving average of $313.21. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.12 and a current ratio of 2.82. West Pharmaceutical Services has a 52-week low of $223.83 and a 52-week high of $438.27. The firm has a market capitalization of $29.05 billion, a PE ratio of 46.32, a P/E/G ratio of 2.75 and a beta of 1.13.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, October 29th. The medical instruments supplier reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.20 by $0.46. The company had revenue of $874.50 million during the quarter, compared to the consensus estimate of $827.12 million. West Pharmaceutical Services had a return on equity of 21.78% and a net margin of 18.81%. The firm’s revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.96 EPS. Analysts forecast that West Pharmaceutical Services will post 9.45 EPS for the current year.

West Pharmaceutical Services Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 18th. Shareholders of record on Wednesday, November 11th will be issued a dividend of $0.26 per share. This is a boost from West Pharmaceutical Services’s previous quarterly dividend of $0.22. The ex-dividend date of this dividend is Tuesday, November 10th. This represents a $1.04 annualized dividend and a dividend yield of 0.3%. West Pharmaceutical Services’s payout ratio is currently 11.67%.

Insider Buying and Selling at West Pharmaceutical Services

In other news, VP Annette Favorite sold 8,135 shares of West Pharmaceutical Services stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $340.81, for a total value of $2,772,489.35. Following the sale, the vice president directly owned 16,845 shares of the company’s stock, valued at approximately $5,740,944.45. The trade was a 32.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 15,659 shares of company stock worth $5,443,749 in the last ninety days. Company insiders own 0.60% of the company’s stock.

Institutional Investors Weigh In On West Pharmaceutical Services

Several institutional investors have recently made changes to their positions in WST. BlackRock Inc. bought a new stake in West Pharmaceutical Services during the 2nd quarter valued at $2,387,990,000. Bank of New York Mellon Corp purchased a new position in shares of West Pharmaceutical Services in the second quarter worth $733,733,000. Generation Investment Management LLP purchased a new stake in West Pharmaceutical Services in the second quarter valued at approximately $728,168,000. Findlay Park Partners LLP acquired a new stake in shares of West Pharmaceutical Services in the second quarter worth $214,196,000. Finally, Legal & General Group Plc purchased a new position in shares of West Pharmaceutical Services during the 2nd quarter valued at about $176,138,000. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services News Roundup

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Q3 results exceeded expectations: West reported adjusted earnings of $2.66 per share, above the $2.20 consensus estimate, while revenue rose 8.7% year over year to $874.5 million, surpassing the $827.1 million forecast. West Reports Third-Quarter 2026 Results
• Positive Sentiment: Higher 2026 outlook: Management raised full-year revenue guidance to $3.41 billion-$3.42 billion from $3.345 billion-$3.380 billion and lifted adjusted EPS guidance to $9.38-$9.48 from $8.85-$9.05. West Pharmaceutical Services Raises Annual Outlook
• Positive Sentiment: Strong high-value product demand: High-Value Product Components sales increased 19.7% and accounted for 53% of quarterly sales, supporting margin expansion and confidence in the company’s growth mix. West Pharma Q3 Earnings Rise on HVP Strength
• Positive Sentiment: Barclays raised its price target to $500 from $440 and maintained an “overweight” rating, implying additional upside based on the referenced share price. Barclays Raises West Pharmaceutical Price Target
• Neutral Sentiment: Institutional positioning was mixed, with several large funds adding shares while others reduced or exited positions. Recent insider activity also showed sales rather than purchases, though these transactions may not reflect the company’s operating outlook.
• Negative Sentiment: Valuation remains a risk after the rally, with the stock trading at a high earnings multiple. One analysis also cautioned that declining cash flow may leave the shares overvalued if earnings growth moderates. West Stock Could Be Overvalued

About West Pharmaceutical Services

West Pharmaceutical Services, Inc develops and manufactures components and delivery systems used in the administration and packaging of injectable medicines and other healthcare products. Its offerings include elastomer closures, seals, syringe components, drug-delivery systems, and other specialized packaging components designed to support the safety, quality, and performance of pharmaceutical products.

The company also provides contract-manufacturing services for pharmaceutical, biotechnology, and medical-device customers.